Abbott Laboratories stock (US0028241000): diabetes segment drives attention after latest quarterly update

Abbott Laboratories recently reported fresh quarterly figures and highlighted continued growth in its medical device and diabetes care business, keeping the healthcare stock in focus for US investors.

Abbott Laboratories remains a closely watched healthcare stock after the company reported its latest quarterly results and provided updated commentary on demand trends in diagnostics, medical devices and diabetes care. The diversified group, which is best known to many investors for its FreeStyle Libre glucose monitoring systems and a broad range of medical devices and nutritional products, reaffirmed its role as a bellwether for parts of the US and global healthcare market in the new reporting season, according to information published by the company and major financial media in April 2026.

In its first-quarter 2026 earnings release, Abbott Laboratories reported continued revenue growth and highlighted solid contributions from its medical device segment, particularly diabetes care. The company also discussed its outlook for the remainder of the year and confirmed full-year guidance ranges for earnings per share, pointing to expected growth in core businesses even as COVID-related testing revenues continue to normalize, according to the earnings announcement made available on the company’s investor relations website in April 2026 and coverage from international business media as of April 2026.

As of: 17.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Abbott Laboratories
• Sector/industry: Healthcare, medical devices, diagnostics and nutrition
• Headquarters/country: United States
• Core markets: North America, Europe, Asia-Pacific and emerging markets
• Key revenue drivers: Medical devices including diabetes care, diagnostics and nutritional products
• Home exchange/listing venue: New York Stock Exchange (ticker: ABT)
• Trading currency: US dollar (USD)

Abbott Laboratories: core business model

Abbott Laboratories operates as a diversified healthcare company with four major business segments: medical devices, diagnostics, nutritional products and established pharmaceuticals. Through this portfolio, the group generates revenue from both hospital and outpatient settings and from consumer-facing products, creating multiple revenue streams that are exposed to trends such as aging populations, rising prevalence of chronic diseases and expanding access to healthcare in emerging markets, as described in the company’s annual report for 2025 published in early 2026 and summarized by global financial media in February 2026.

The medical device segment includes cardiovascular and structural heart products, neuromodulation devices and diabetes care systems. One of the most prominent product families is the FreeStyle Libre continuous glucose monitoring platform, which is used by millions of people living with diabetes worldwide and provides Abbott Laboratories with recurring revenue through sensors, readers and connected digital services, according to product information and investor presentations referenced in the company’s 2025 annual filing as of February 2026 and industry commentary from healthcare analysts in March 2026.

Diagnostics form another essential pillar of Abbott Laboratories’ business model. The company offers laboratory systems for hospitals and clinics as well as point-of-care testing solutions. During the pandemic, COVID-19 testing provided a temporary boost to revenue, but this portion has been declining as testing volumes normalize, leaving core diagnostics platforms and other tests as the main drivers. This shift has been emphasized in the firm’s recent quarterly updates, where management noted that investors should focus on underlying diagnostics growth rather than pandemic-related contributions, according to the Q1 2026 earnings materials published in April 2026 and coverage by major US financial news outlets as of April 2026.

Nutritional products and established pharmaceutical brands complete the portfolio. In nutrition, Abbott Laboratories sells infant formulas, adult nutrition products and specialty formulations. The company experienced notable disruption in US infant formula in previous years due to supply and regulatory issues, but has been working to rebuild its position in this market while expanding other nutrition categories, as outlined in management’s comments in the 2025 annual report released in early 2026 and follow-up analysis in US business press in March 2026. Established pharmaceuticals mainly target emerging markets, where Abbott Laboratories markets branded generics in therapeutic areas such as gastroenterology, cardiology and women’s health.

This structure positions Abbott Laboratories as a broad healthcare supplier rather than a single-product story. For investors, that diversification means that trends in different parts of the healthcare ecosystem can offset each other, while also giving the company exposure to long-term demand drivers such as chronic disease management and demographic change, as discussed in sector overviews from leading investment banks and health economics research houses in the first quarter of 2026.

Main revenue and product drivers for Abbott Laboratories

In the most recent quarter, Abbott Laboratories underscored that medical devices, and especially diabetes care, remain central growth engines. The company reported that diabetes care revenue increased at a double-digit rate year on year, driven by continued uptake of FreeStyle Libre systems in both the United States and international markets. Management highlighted strong adoption among type 2 diabetes patients and expanding reimbursement coverage in multiple countries, according to the Q1 2026 earnings release published in April 2026 and a conference call transcript cited by international financial media as of April 2026.

Beyond diabetes, cardiovascular and structural heart products also contributed to device segment growth. Abbott Laboratories pointed to demand for minimally invasive procedures supported by its portfolio of transcatheter devices and heart failure monitoring systems. These therapies benefit from hospitals catching up on deferred procedures from the pandemic era and from an aging population requiring more cardiovascular interventions, as described by company executives during the Q1 2026 earnings call in April 2026 and summarized by US healthcare-focused news services as of April 2026.

In diagnostics, routine testing volumes across hospital and laboratory customers remained stable to slightly higher, while COVID-19 testing continued to decline versus the prior year. Abbott Laboratories noted that the pandemic-related testing windfall is now largely behind the company, and that investors should track core diagnostics growth metrics and market share developments in laboratory instruments and assays. This was stated in the Q1 2026 results commentary released in April 2026 and echoed in coverage by international business media as of April 2026, which emphasized the transition from pandemic to post-pandemic revenue mix.

Nutritional products performed more steadily in the latest period. Abbott Laboratories reported ongoing recovery in its US infant formula operations and growth in certain adult nutrition brands. However, management acknowledged that competition in global nutrition remains intense, with pricing, branding and distribution all playing important roles. The company is focusing on innovation and capacity optimization to strengthen this segment, according to remarks in the 2025 annual report published in early 2026 and follow-up comments during the Q1 2026 earnings call in April 2026, as reported by US financial news outlets as of April 2026.

Established pharmaceuticals, which are primarily sold in emerging markets, continued to contribute steady cash flows. Abbott Laboratories highlighted demand in regions such as Latin America and parts of Asia, where growing middle classes and expanding healthcare coverage support consumption of branded generics. Currency fluctuations and local regulatory environments remain key variables for this segment, as explained in the company’s 2025 annual report released in February 2026 and in regional market commentaries from international financial media as of March 2026.

The company’s guidance for full-year 2026, reaffirmed with the Q1 2026 update, reflects expectations for growth in underlying businesses while acknowledging headwinds from the normalization of COVID testing and currency movements. Abbott Laboratories provided a range for adjusted earnings per share and indicated that capital allocation priorities include research and development, targeted acquisitions, dividends and share repurchases, according to the guidance section of the Q1 2026 earnings release published in April 2026 and coverage by major US financial media as of April 2026.

Industry trends and competitive position

Abbott Laboratories operates in competitive healthcare markets that are shaped by demographic trends, technological innovation and regulatory frameworks. In diabetes care, the company competes with other major suppliers of continuous glucose monitoring and insulin delivery technologies. Industry research points to continued strong growth in the global diabetes technology market as awareness, reimbursement and adoption increase, particularly for type 2 patients who historically relied on less sophisticated monitoring methods, according to market studies from healthcare analytics firms published in late 2025 and early 2026 and cited by financial media in January 2026.

In diagnostics, Abbott Laboratories faces competition from global peers offering laboratory instruments, assays and point-of-care solutions. Hospitals and laboratories often sign multi-year contracts that involve both equipment and consumables, creating recurring revenue but also requiring sustained investment in innovation and customer service. Sector analyses from leading investment banks and industry consultants in the first quarter of 2026 highlighted that scale, menu breadth and automation capabilities are key competitive advantages, and Abbott Laboratories is frequently mentioned as one of the established players in this space based on 2025 revenue rankings.

The nutritional segment pits Abbott Laboratories against both multinational food companies and specialized nutrition providers. Product recalls or supply disruptions can have reputational and financial impacts, as seen in earlier years in the US infant formula market. This experience has led the company to emphasize quality, regulatory compliance and capacity planning in its communications with investors, as referenced in the 2025 annual report published in early 2026 and related commentary from US business media in March 2026. In established pharmaceuticals, differentiation comes from brand recognition, local distribution networks and portfolio breadth in key therapeutic areas.

Overall, the company’s diversified footprint across devices, diagnostics, nutrition and pharmaceuticals provides multiple avenues for growth but also subjects Abbott Laboratories to competitive pressures from large global groups and regional specialists. For investors, this means that monitoring product pipelines, regulatory milestones and competitor launches is essential when assessing the company’s medium-term prospects, as emphasized in sector outlooks from international research organizations and financial news services during the first months of 2026.

Why Abbott Laboratories matters for US investors

Abbott Laboratories is listed on the New York Stock Exchange under the ticker ABT and is a component of major US equity indices followed by institutional and retail investors. As a large-cap healthcare stock with significant US operations and a global footprint, it offers exposure to several long-term themes, including aging populations, chronic disease management and expanding healthcare access in emerging markets, according to index fact sheets and sector overviews published by leading US financial institutions in early 2026 and summarized in financial news reports as of March 2026.

For US investors, the company’s earnings development can provide insights into broader healthcare demand trends. For example, changes in procedure volumes reported by Abbott Laboratories’ medical device segment can hint at how hospitals are managing elective surgeries, while diagnostics orders may reflect testing patterns across healthcare systems. These data points are often discussed in earnings coverage by US financial media, which in April 2026 highlighted the implications of Abbott Laboratories’ Q1 2026 figures for the wider medical technology and diagnostics landscape.

Dividend payments are another element that draws attention from income-oriented US investors. Abbott Laboratories has a long history of regular dividend distributions and has been included in lists of companies with extended dividend track records, according to compilations by US financial research providers published in late 2025 and referenced in business press coverage in early 2026. The company’s capital allocation framework, which balances dividends, research and development, selective acquisitions and share repurchases, is regularly reviewed during quarterly earnings calls and capital markets communications.

Because Abbott Laboratories operates in heavily regulated markets, US investors also monitor developments from agencies such as the US Food and Drug Administration. Approvals or labeling changes for key devices and diagnostics can affect revenue trajectories. Recent regulatory updates related to diabetes care and cardiovascular devices were discussed by the company and reported in specialized medical technology media during the first quarter of 2026, underscoring the importance of regulatory milestones for the stock’s risk-return profile.

What type of investor might consider Abbott Laboratories – and who should be cautious?

Investors who follow large-cap healthcare names often look at Abbott Laboratories as part of a diversified portfolio that seeks exposure to defensive sectors with structural growth drivers. The company’s mix of recurring revenue from medical devices and diagnostics consumables, alongside cash flows from nutrition and established pharmaceuticals, tends to appeal to those who value business models with multiple product lines and geographic diversification, as noted in portfolio strategy commentaries from US wealth management firms published in early 2026 and reported by financial media as of March 2026.

On the other hand, investors with a preference for highly focused, high-growth biotechnology or early-stage medical technology companies might view Abbott Laboratories as more of a stable growth or core holding rather than a pure-play innovation vehicle. While the company invests significantly in research and development and regularly launches new products, its scale and breadth mean that individual product successes or setbacks are often diluted across the broader portfolio, which can be both a strength and a limitation, according to equity strategy notes from investment banks and asset managers issued in the first quarter of 2026.

Risk-averse investors should be aware that, despite the relatively defensive nature of many healthcare revenues, Abbott Laboratories is still exposed to factors such as regulatory risk, pricing pressure, competitive dynamics and macroeconomic conditions that can influence procedure volumes and healthcare budgets. Currency fluctuations can also affect reported results given the group’s sizable international exposure. These aspects have been highlighted repeatedly in the risk sections of the company’s 2025 annual report published in early 2026 and in independent assessments from credit rating agencies and financial news outlets as of February and March 2026.

Risks and open questions

Among the key risks identified by observers are regulatory and quality-related challenges. Previous disruptions in the US infant formula business demonstrated that safety findings, plant shutdowns or recalls can have material financial and reputational effects. Abbott Laboratories has taken steps to address these issues and has communicated enhancements to quality controls and manufacturing resilience, but investors continue to monitor regulatory communications and capacity utilization, according to the 2025 annual report released in early 2026 and follow-up media coverage in March 2026.

Competitive intensity in diabetes technology is another area closely watched by the market. Rival companies are investing heavily in continuous glucose monitoring, insulin pumps and integrated digital ecosystems. Pricing pressure, reimbursement decisions and technological differentiation will play important roles in shaping growth and profitability. Analysts cited by US financial media in the first quarter of 2026 have pointed out that maintaining leadership in FreeStyle Libre and expanding into new patient segments are central strategic tasks for Abbott Laboratories in the coming years.

Macroeconomic and policy factors also represent important uncertainties. Changes in healthcare reimbursement frameworks in the United States or major international markets could influence demand for diagnostics and medical devices. Currency volatility can affect reported revenue and margins, particularly in emerging markets where the company sells established pharmaceuticals. These topics are regularly discussed in the risk disclosures of Abbott Laboratories’ regulatory filings and in commentary from international financial media, including reports published around the release of the 2025 annual report and the Q1 2026 earnings announcement.

Key dates and catalysts to watch

Looking ahead, investors will pay attention to Abbott Laboratories’ upcoming quarterly earnings releases, where the company will update the market on revenue growth in medical devices and diagnostics, progress in nutrition and established pharmaceuticals and any revisions to full-year guidance. The timing of these reports typically follows a regular quarterly calendar that is communicated on the investor relations website and in financial media calendars, with the next update expected in the second half of 2026 based on the pattern of prior years’ reporting dates, as noted in coverage by US financial news outlets in April 2026.

Beyond scheduled results, potential catalysts include regulatory approvals for new medical devices or indications, milestones related to diabetes technology platforms and developments in the US nutrition business. Industry conferences and medical congresses, where Abbott Laboratories often presents clinical data or product updates, can also influence investor sentiment. Financial media and sector analysts routinely track these events, as illustrated by the attention paid to presentations and announcements made during major cardiology and diabetes conferences in late 2025 and early 2026, which were reported in specialized healthcare news services and broader business outlets at the time.

Conclusion

Abbott Laboratories enters the remainder of 2026 with momentum in core medical device and diagnostics businesses, supported particularly by ongoing adoption of its FreeStyle Libre diabetes platform and an improving picture in routine testing. At the same time, the company continues to navigate competitive and regulatory challenges in nutrition and other segments, while managing the transition away from pandemic-driven testing revenues. For US investors, the stock offers exposure to a diversified healthcare portfolio with global reach, but also requires careful monitoring of product innovation, regulatory developments and execution in key markets. How effectively Abbott Laboratories balances growth opportunities with the operational and regulatory complexities of its broad portfolio will likely remain a central question for the market in the coming quarters.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.